Results 141 to 150 of about 26,198 (189)

Therapeutic monitoring of unfractionated heparin – trials and tribulations

Expert Review of Hematology, 2017
Heparin is one of the oldest biological medicines with an established role in prevention and treatment of arterial and venous thromboembolism. Published therapeutic ranges for unfractionated heparin (UFH) mostly precede the large increase in the number of activated partial thromboplastin time (APTT) reagent/instrument combinations that now show wide ...
Leonardo Pasalic
exaly   +3 more sources

Laboratory Monitoring of Unfractionated Heparin Treatment

Clinics in Laboratory Medicine, 1995
Laboratory monitoring is indicated when unfractionated heparin is used in the treatment of established thromboses. Special problems may be encountered in patients with antithrombin III alteration, thrombocytopenia, heparin resistance, or with an increased risk of bleeding.
openaire   +2 more sources

Unfractionated Heparin and Low-Molecular-Weight Heparin

2018
Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are highly utilized throughout inpatient and ambulatory care settings for many indications, including the treatment of venous thromboembolism, thromboprophylaxis, and acute coronary syndromes.
Rhynn J. Malloy, Jessica Rimsans, Megan Rhoten, Katelyn Sylvester, John Fanikos   +4 more
openaire   +1 more source

Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin

Neurology, 2004
The risk for immune-mediated heparin-induced thrombocytopenia (HIT) in neurologic patients receiving unfractionated heparin (UFH) is not known. In a prospective study of 200 patients, the authors found a 2.5% rate of HIT and a 2% rate of HIT-associated thromboses, suggesting that neurologic patients treated with UFH are at considerable risk for ...
U, Harbrecht, B, Bastians, A, Kredteck, P, Hanfland, T, Klockgether, C, Pohl   +5 more
openaire   +2 more sources

Dosing of Unfractionated Heparin in Acute Coronary Syndromes

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
Although the use of low‐molecular‐weight heparins for treatment of acute coronary syndromes (ACS) has increased in recent years, unfractionated heparin (UFH) remains the drug of choice for many patients and institutions. One reason is that this agent is safe for patients with renal dysfunction as well as those who undergo percutaneous coronary ...
Omar, Badawi, Lance J, Oyen, Stuart T, Haines   +2 more
openaire   +2 more sources

The Use of Unfractionated Heparin and Low Molecular Weight Heparins in Pregnancy

Clinical Obstetrics & Gynecology, 2006
Currently unfractionated heparin (UH) and low molecular weight heparins (LMWH) are the agents of choice for anticoagulation in pregnancy. LMWH have been used safely without monitoring in nonpregnant patients; however, because of documented changes in the pharmacokinetics of these agents in pregnancy, monitoring with anti-Xa levels is necessary in ...
openaire   +2 more sources

Effects of Unfractionated and Fractionated Heparin on Platelet Function

Haemostasis, 2009
Heparin-induced alterations of platelet function have repeatedly been reported over the last 30 years. The development of low-molecular-weight (LMW) heparin fractions prompted us to compare the effect of unfractionated (UF) heparin and LMW heparin on platelet function.
D, Heinrich, T, Görg, M, Schulz
openaire   +2 more sources

Unfractionated Heparin and Low Molecular Weight Heparin

2015
Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) are parenteral anticoagulants commonly used to prevent and treat thromboembolism. These agents are included on the Institute for Safe Medication Practices (ISMP) list of medications that have an increased risk of causing severe patient injury when used in error.
openaire   +1 more source

The APTT Response of Pregnant Plasma to Unfractionated Heparin

Thrombosis and Haemostasis, 2002
SummaryPregnancy is associated with a physiological increase in coagulation factors and heparin binding proteins; both can affect the activated partial thromboplastin time (APTT) in response to unfractionated heparin (UFH) invalidating the use of a non-pregnant APTT therapeutic range.
S D, Chunilal, E, Young, M A, Johnston, C, Robertson, I, Naguit, P, Stevens, D, Galashan, M L, Oskamp, B, Brennan, J S, Ginsberg   +9 more
openaire   +2 more sources

Management of prosthetic valve thrombosis with unfractionated heparin

International Journal of Cardiology
Prosthetic valve thrombosis (PVT) is a severe and life-threatening complication. Surgery and thrombolytic therapy (TT) carry a high risk, and in several circumstances, optimal anticoagulation with unfractionated heparin (UFH) infusion may be an alternative treatment.
Semih, Kalkan, Mustafa Ozan, Gürsoy, Ahmet, Güner, Macit, Kalçık, Emrah, Bayam, Sabahattin, Gündüz, Mehmet, Özkan   +6 more
openaire   +2 more sources